These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38069816)

  • 1. Conformational Selectivity of ITK Inhibitors: Insights from Molecular Dynamics Simulations.
    Ogawa N; Ohta M; Ikeguchi M
    J Chem Inf Model; 2023 Dec; 63(24):7860-7872. PubMed ID: 38069816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a New Inhibitor That Stabilizes Interleukin-2-Inducible T-Cell Kinase in Its Inactive Conformation.
    Hantani R; Hanawa S; Oie S; Umetani K; Sato T; Hantani Y
    SLAS Discov; 2019 Sep; 24(8):854-862. PubMed ID: 31247148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).
    Tang G; Liu L; Wang X; Pan Z
    Eur J Med Chem; 2019 Jul; 173():167-183. PubMed ID: 30999237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of inactive conformation-selective interleukin-2-inducible T-cell kinase (ITK) inhibitors based on second-harmonic generation.
    Hantani Y; Iio K; Hantani R; Umetani K; Sato T; Young T; Connell K; Kintz S; Salafsky J
    FEBS Open Bio; 2018 Sep; 8(9):1412-1423. PubMed ID: 30186743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK).
    Wang X; Xue G; Pan Z
    Eur J Med Chem; 2020 Feb; 187():111918. PubMed ID: 31830635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolutionary divergence in the conformational landscapes of tyrosine vs serine/threonine kinases.
    Gizzio J; Thakur A; Haldane A; Levy RM
    Elife; 2022 Dec; 11():. PubMed ID: 36562610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent inhibitors for interleukin-2-inducible T-cell kinase: structure-based virtual screening and molecular dynamics simulation approaches.
    Meganathan C; Sakkiah S; Lee Y; Narayanan JV; Lee KW
    J Mol Model; 2013 Feb; 19(2):715-26. PubMed ID: 23015102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.
    Han S; Czerwinski RM; Caspers NL; Limburg DC; Ding W; Wang H; Ohren JF; Rajamohan F; McLellan TJ; Unwalla R; Choi C; Parikh MD; Seth N; Edmonds J; Phillips C; Shakya S; Li X; Spaulding V; Hughes S; Cook A; Robinson C; Mathias JP; Navratilova I; Medley QG; Anderson DR; Kurumbail RG; Aulabaugh A
    Biochem J; 2014 Jun; 460(2):211-22. PubMed ID: 24593284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
    Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
    J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
    Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.
    Ding X; Liu X; Song X; Yao J
    Mol Inform; 2016 Oct; 35(10):529-537. PubMed ID: 27643705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Itk inhibitors: a patent review.
    Lo HY
    Expert Opin Ther Pat; 2010 Apr; 20(4):459-69. PubMed ID: 20218931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
    Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
    PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of IL-2 inducible tyrosine kinase inhibitors by quantum mechanics and ligand based virtual screening approaches.
    Khan A; Zia K; Khan SA; Khalid A; Abdalla AN; Bibi M; Ul-Haq Z
    J Biomol Struct Dyn; 2024 Apr; 42(7):3630-3640. PubMed ID: 37216319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.
    Zhong Y; Dong S; Strattan E; Ren L; Butchar JP; Thornton K; Mishra A; Porcu P; Bradshaw JM; Bisconte A; Owens TD; Verner E; Brameld KA; Funk JO; Hill RJ; Johnson AJ; Dubovsky JA
    J Biol Chem; 2015 Mar; 290(10):5960-78. PubMed ID: 25593320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK).
    Trani G; Barker JJ; Bromidge SM; Brookfield FA; Burch JD; Chen Y; Eigenbrot C; Heifetz A; Ismaili MHA; Johnson A; Krülle TM; MacKinnon CH; Maghames R; McEwan PA; Montalbetti CAGN; Ortwine DF; Pérez-Fuertes Y; Vaidya DG; Wang X; Zarrin AA; Pei Z
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5818-5823. PubMed ID: 25455497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights in protein kinase conformational dynamics.
    Saladino G; Gervasio FL
    Curr Top Med Chem; 2012; 12(17):1889-95. PubMed ID: 23116468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
    Zhao H; Huang D; Caflisch A
    ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.
    McLean LR; Zhang Y; Zaidi N; Bi X; Wang R; Dharanipragada R; Jurcak JG; Gillespy TA; Zhao Z; Musick KY; Choi YM; Barrague M; Peppard J; Smicker M; Duguid M; Parkar A; Fordham J; Kominos D
    Bioorg Med Chem Lett; 2012 May; 22(9):3296-300. PubMed ID: 22464456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.